Satellite Symposia and Product Theaters

THSNA is happy to present the 2024 Satellite Symposium Program. Please note the following:

  • Each event is planned independently of the THSNA program committee and THSNA does not endorse the programming content.
  • You must be a THSNA registrant in order to attend any satellite symposia.
  • There is no cost to attend these symposia.
  • All symposia occur during a meal and food will be provided.
  • If a pre-registration link is not provided, all admittance will be on a first-come, first-served basis.
  • Any pre-registrants not present at the session room door 10 minutes prior to the start of the program will be removed from the pre-registrant list.

Thursday, April 4 - Breakfast

Reinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment, including the latest data in infants: Join the conversation with Dr. Mike Silvey

Sponsored By: Genentech

7:15 - 8:15 AM, Chicago Ballroom IX-X
Please join us for an engaging program led by Dr. Mike Silvey as he shares his perspectives on managing patients with hemophilia A using a subcutaneous prophylactic treatment. The presentation will include the pivotal efficacy and safety data that is the foundation of the ongoing clinical trial program in patients with and without FVIII inhibitors, including an overview of real-world experience. He’ll also share updates from the latest trial in infants and previously untreated patients. The presentation will feature brain teasers, showcase social media that’s engaging the hemophilia community, and Mythbuster polls. Be sure to bring your questions to the Q&A following the program.


Ready, Set, Go! Shape the Future of Care in von Willebrand Disease

Sponsored By: Octapharma

7:15 - 8:15 AM , Chicago Ballroom VI
Join our distinguished faculty; Dr Veronica Flood, Dr Jill Johnsen, and Dr Shveta Gupta to explore the future of care in von Willebrand disease. The panel will discuss the diagnosis of von Willebrand disease, including identification of iron deficiency and genotyping, and the importance of prophylaxis in VWD patients. The results of the WIL-31 study will be presented, the largest prospective prophylaxis study in von Willebrand disease with an on-demand run-in study as an intra-individual patient comparator. We look forward to seeing you in Chicago!

Thursday, April 4 - Lunch

More Than Carriers: Recognizing and Managing Women and Girls With Hemophilia

Sponsored By: Novo Nordisk

11:45 AM - 12:45 PM , Chicago Ballroom IX-X
To highlight Novo Nordisk’s long-standing commitment to women and girls with rare bleeding disorders, this interactive program will discuss the unique challenges women and girls with hemophilia experience and will highlight the serious consequences that may arise in those who are not diagnosed and treated appropriately. Many women and girls are more than carriers, and they may experience added complications during menstruation, pregnancy, labor, and delivery. Practical guidance for managing hemophilia in women and girls will be presented, including available resources for providers and patients


Real-world experiences with ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc- Von Willebrand Factor XTEN Fusion Protein]: A first-in-class treatment option

Sponsored By: Sanofi

11:45 AM - 12:45 PM , Chicago Ballroom VI

Join us for a conversation about the mechanism of extension, pharmacokinetics, efficacy, dosing and safety information from the XTEND-1 clinical trial, as well as real-world clinical cases with ALTUVIIIO. This presentation will feature a live patient perspective.

Thursday, April 4 - Dinner

Clinical & Patient Perspective: A Treatment for Adults with Acute Hepatic Porphyria, including Acute Intermittent Porphyria

Sponsored by: Alnylam Pharmaceuticals

5:30 - 6:30 PM , Chicago Ballroom VI
Acute hepatic porphyria (AHP) is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks. The cardinal symptom of an AHP attack is severe, diffuse abdominal pain. Led by Dr. Lisa Boggio, a consultant of Alnylam Pharmaceuticals, this presentation will provide a disease overview and review the clinical profile of a treatment for adults with AHP, featuring Phase 3 Study results and open-label extension data.

Attendees will also hear from an AHP patient who will share their experience with the disease and treatment.

Please join Alnylam Pharmaceuticals and Dr. Boggio to learn more about this treatment for adults with AHP. Dinner will be provided for attendees.


Gene Therapy for Hemophilia B: Sharing Experiences in Real-World Settings

Sponsored By: CSL Behring

5:30 - 6:30 PM , Chicago Ballroom IX-X
Despite meaningful improvements in treatment for hemophilia B, there remains a need for new therapeutic options that will reduce bleeds, reduce or eliminate the need for routine factor IX prophylaxis, and provide long-term benefits of sustained factor IX activity levels. The first ever FDA-approved gene therapy for hemophilia B is designed to reduce the burden of disease on patients’ lives by addressing these unmet needs.

Join our educational product theater session as a team of hemophilia B experts discuss the clinical data and the patient and HCP journey towards treatment as well as share their clinical experiences with gene therapy for hemophilia B.

Continuing education credits will not be offered for this program.

Friday, April 5 - Breakfast

Hemostasis 2.0: Rethinking Hemophilia Management and Monitoring with Anti-TFPIs and FVIII Mimetics

In partnership with CME Outfitters, LLC. Supported by an educational grant from Novo Nordisk, Inc.

7:00 - 8:00 AM , Chicago Ballroom IX-X
In this CME Outfitters live activity, experts in hemophilia, including a patient who has lived with the disorder for many years, discuss the role of these newer therapies, how they work, and how to implement them in practice to improve quality of care and outcomes. A focused exercise in shared decision making keeps the conversation grounded in counseling and care and includes both clinician and patient perspectives.

This activity is certified for 1.0 hours of ACCME, ANCC, AAPA, and ABIM MOC II credit.


Advances in iTTP management – Contemporary Clinical Approaches

Sponsored By: Sanofi

7:00 - 8:00 AM , Chicago Ballroom VI
Please join our Sanofi Medical Affairs Rare Blood Disorders team for our medical symposium to gain expert insights on prioritizing clinical management of aTTP/iTTP, focusing on early treatment, and achieving durable responses from therapies, ultimately resulting in improved clinical outcomes. The symposium will be presented in two parts and will illustratively describe the iTTP pathophysiology, epidemiology/diagnostic considerations, before discussing the ISTH guidelines on diagnosis and treatment of iTTP and important implications on clinical management of iTTP.


Friday, April 5

The Role of the Liver in Hemophilia Gene Therapy & Clinical Implications

Sponsored by: Pfizer

11:45 AM - 12:45 PM , Chicago Ballroom VI
The advent of liver directed-gene therapies in hemophilia has placed increasing interest on liver health in the pre and post infusion settings. This session will explore the role of the liver in hemophilia gene therapy including evaluation of liver heath and key considerations for clinical management from a hepatologist’s perspective.


GVONVENDI Prophylaxis for Severe Type 3 von Willebrand Disease – Patient Case Discussion

Sponsored By: Takeda Pharmaceuticals

11:45 AM - 12:45 PM , Chicago Ballroom IX-X
Join our expert HCP and a patient living with von Willebrand Disease (VWD) for an interactive journey. Our panel will guide you through the patient’s experience with VWD, review their treatment history, and discuss how VONVENDI may be added to the treatment plan for prophylaxis.

Friday, April 5 - Dinner

Ask the Experts: Navigating Gene Therapy for Hemophilia – Lived Experience Perspectives from Patients and Providers

Sponsored By: BioMarin

7:00 - 8:00 PM, Chicago Ballroom IX-X
Join us for dinner and hear from a panel of health care providers with hemophilia gene therapy experience (clinical trial and post-FDA approval), as well as patients with years of post-treatment experience. Panelists will review clinical trial data and discuss patient treatment outcomes and expectations. Have your questions answered by the panel and learn how gene therapy can be implemented in your Hemophilia Treatment Center.


Elevating Hemophilia Care Beyond Bleed Management: A Multidisciplinary Panel Dialogue to Bridge Gaps in Patient Care

Sponsored By: Sanofi

7:00 - 8:00 PM , Chicago Ballroom VI
Please join us for our panel of healthcare providers and patients/caregivers for a discussion on current unmet needs in hemophilia centered around findings from a Hemophilia Life Stages and Changes Global Survey of >2,700 patients, caregivers, and hematologists. As treatment options evolve, so must expectations and goals on management of hemophilia. This symposium will explore how communication gaps between HCPs and patients can improve to achieve positive change and better quality of life.


Saturday, April 6 - Breakfast

Paradigm Shifts in Hemophilia Prophylaxis: Putting Evidence Into Practice (Sponsored by Clinical Care Options, LLC)

Sponsored By: Clinical Care Options

7:00 - 8:00 AM , Chicago Ballroom IX-X
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Finding the Trusted Factor: 10 Years of FIX Experience Across Ages and Settings

Sponsored By: Sanofi

7:00 - 8:00 AM, Chicago Ballroom VI
This presentation highlights a decade of experience (since FDA approval) with a Factor IX therapy, exploring its impact across various age groups and settings. You will hear from clinical experts and a patient as they share insights and experience with an EHL FIX therapy that has been trusted for 10 years.